증례
Granulocyte-Colony Stimulating Factor 투여 후 발생한 돌발성 난청
김선린1, 오세준1, 공수근1, 고의경1,*
Sudden Sensorineural Hearing Loss after Granulocyte-Colony Stimulating Factor Administration
Seon-Lin Kim1, Se-Joon Oh1, Soo-Keun Kong1, Eui-Kyung Goh1,*
1Department of Otorhinolaryngology-Head and Neck Surgery, Pusan National University College of Medicine and Medical Research Institute, Busan, Korea
*교신저자: 고의경, 49241 부산광역시 서구 구덕로 179 부산대학교 의과대학 이비인후과학교실 전화: (051) 240-7335·전송: (051) 246-8668 E-mail:
gohek@pusan.ac.kr
© Copyright 2018 The Busan, Ulsan, Gyeoungnam Branch of Korean Society of Otolaryngology-Head and Neck Surgery. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: Mar 22, 2018; Revised: Apr 25, 2018; Accepted: May 24, 2018
Published Online: May 31, 2020
ABSTRACT
Filgrastim® (Granulocyte-colony stimulating factor, G-CSF) is generally used to promote the increase of neutrophils to patients with neutropenia during chemotherapy or donors for hematopoietic stem cell transplantation (HSCT). Its adverse effects were mainly reported as non-serious symptoms, such as back pain, headache, arthralgia and fever. A 29-year-old male was administered the Filgrastim as a HSCT donor. He accompanied left side hearing disturbance and tinnitus after 2 days from administration of the drug. He admitted to our department and underwent improvement of hearing after high dose steroid therapy. In this report, we describe a case of sudden sensorineural hearing loss (SSNHL) as an unreported adverse effect of G-CSF in the literature. (J Clinical Otolaryngol 2018;29:87-90)
Keywords: 과립구 세포군 촉진인자; 호중구림프구 비; 돌발성 난청
Keywords: Filgrastim; Neutrophil-to-lymphocyte ratio; Sudden sensorineural hearing loss; Granulocyte-colony stimulating factor
